{"url_path":"/sec/bixt/8-k/2026-08-11/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1445815/0001493152-26-036977-index.html","accession_number":"0001493152-26-036977","cik":"0001445815","ticker":"BIXT","issuer_name":"BIOXYTRAN, INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1445815/0001493152-26-036977-index.html","primary_entity_key":"0001445815","primary_entity_name":"BIOXYTRAN, INC"},"word_count":107,"has_tables":true,"body_markdown":"** **\n\n**Item\n9.01 Financial Statements and Exhibits.**\n\n \n\n**Exhibit**\n\n**Number**\n\n \n**Description**\n\n \n \n \n\n99.1*\n\n[Press Release dated August 11, 2026, entitled “*Bioxytran Reports Encouraging Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patient Treated with PLICID, a Novel Galectin Antagonist Designed with Artificial Intelligence*”.](ex99-1.htm)\n\n \n \n \n\n104\n \nCover\nPage Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n*\nFiled as an exhibit hereto.\n\n** **\n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \n**BIOXYTRAN,\nINC.**\n\n \n \n \n\n \nBy:\n*/s/\nDavid Platt, Ph.D.*\n\n \n \nDavid\nPlatt, Ph.D., its Chief Executive Officer\n\n \n \n \n\nDate\nAugust 11, 2026"}